Double-Blind Comparison of the Efficacy of Continued Zidovudine Versus 2',3'-Dideoxyinosine (ddI) (BMY-40900) for the Treatment of Patients With AIDS or AIDS-Related Complex and Increasing Symptomatology Despite Treatment With Zidovudine

NCT00002035 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Zidovudine
DRUG: Didanosine

Sponsor

Bristol-Myers Squibb